Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.
Latta-Mahieu M, Elmer B, Bretteville A, Wang Y, Lopez-Grancha M, Goniot P, Moindrot N, Ferrari P, Blanc V, Schussler N, Brault E, Roudières V, Blanchard V, Yang ZY, Barneoud P, Bertrand P, Roucourt B, Carmans S, Bottelbergs A, Mertens L, Wintmolders C, Larsen P, Hersley C, McGathey T, Racke MM, Liu L, Lu J, O'Neill MJ, Riddell DR, Ebneth A, Nabel GJ, Pradier L. Latta-Mahieu M, et al. Among authors: barneoud p. Glia. 2018 Mar;66(3):492-504. doi: 10.1002/glia.23260. Epub 2017 Nov 14. Glia. 2018. PMID: 29134678
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L, Blanchard-Brégeon V, Bohme A, Debeir T, Menager J, Benoit P, Barneoud P, Taupin V, Bertrand P, Dugay P, Cameron B, Shi Y, Naimi S, Duchesne M, Gagnaire M, Weeden T, Travaline T, Reczek D, Khiroug L, Slaoui M, Brunel P, Fukuyama H, Ravetch J, Canton T, Cohen C. Pradier L, et al. Among authors: barneoud p. Alzheimers Res Ther. 2018 Nov 28;10(1):117. doi: 10.1186/s13195-018-0447-y. Alzheimers Res Ther. 2018. PMID: 30486882 Free PMC article.
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
Delay-Goyet P, Blanchard V, Schussler N, Lopez-Grancha M, Ménager J, Mary V, Sultan E, Buzy A, Guillemot JC, Stemmelin J, Bertrand P, Rooney T, Pradier L, Barnéoud P. Delay-Goyet P, et al. Among authors: barneoud p. Alzheimers Dement (N Y). 2016 Nov 3;2(4):267-280. doi: 10.1016/j.trci.2016.10.002. eCollection 2016 Nov. Alzheimers Dement (N Y). 2016. PMID: 29067314 Free PMC article.
Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration.
Taccola C, Barneoud P, Cartot-Cotton S, Valente D, Schussler N, Saubaméa B, Chasseigneaux S, Cochois V, Mignon V, Curis E, Lochus M, Nicolic S, Dodacki A, Cisternino S, Declèves X, Bourasset F. Taccola C, et al. Among authors: barneoud p. Neuropharmacology. 2021 Jun 15;191:108588. doi: 10.1016/j.neuropharm.2021.108588. Epub 2021 Apr 30. Neuropharmacology. 2021. PMID: 33940010
High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
Taccola C, Cartot-Cotton S, Valente D, Barneoud P, Aubert C, Boutet V, Gallen F, Lochus M, Nicolic S, Dodacki A, Smirnova M, Cisternino S, Declèves X, Bourasset F. Taccola C, et al. Among authors: barneoud p. Eur J Pharm Sci. 2018 May 30;117:68-79. doi: 10.1016/j.ejps.2018.02.005. Epub 2018 Feb 7. Eur J Pharm Sci. 2018. PMID: 29427702
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse D, Malanda A, Peyronel JF, Evanno Y, Lardenois P, De-Peretti D, Abécassis PY, Barnéoud P, Brunel P, Burgevin MC, Cegarra C, Auger F, Dommergue A, Lafon C, Even L, Tsi J, Luc TPH, Almario A, Olivier A, Castel MN, Taupin V, Rooney T, Vigé X. Lesuisse D, et al. Among authors: barneoud p. Bioorg Med Chem Lett. 2019 Apr 1;29(7):929-932. doi: 10.1016/j.bmcl.2019.01.024. Epub 2019 Jan 30. Bioorg Med Chem Lett. 2019. PMID: 30773432
44 results